LSL Pharma Group Inc.

C$0.31As of Sun 8 Nov 2026, 12:00 UTC
TSXV:LSLHealthcare
Country Canada
PE (Fwd) •••
TSR 4Y CAGR (21.13%)
Div yield —
ROE (31.63%)
Drug Manufacturers (Specialty & Generic)
Beta (5Y) (0.41)
PE TTM —
TSR TTM (16.22%)
Mkt cap C$39.29M
ROIC (6.15%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.31
(0.11%)
206.44%
Sell 6|8|1|1|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
—
—
—
—
38.41%
32.26%
14.80%
4.97%
Revenue$M
4.729
4.932
5.114
5.380
9.09%
12.20%
11.49%
19.44%
Peers (US$27.81M)
Cap (US$)
PE
27.70M
—
24.68M
—
Capital
TTM
5Y
10Y
Leveragex
0.446
0.040
0.037
EBIT/Intx
0.978
2.959
3.421
Own earn%
(823.08)
52.06
53.25
Sh yield%
36.29
21.31
24.74
Owners
Insiders/Inst%
3.24
45.12
Short interest%
4.83
SBC / revenue%
4.49
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
28–32
$1 testx
−0.1
Incr. ROIC%
16